Key Findings
A research team at Penn Medicine has developed an advanced artificial intelligence (AI)-driven framework that efficiently and precisely identifies novel target antigens for CAR T-cell therapy. This framework has led to the successful proof-of-concept development of CAR T-cells targeting the glycoprotein GPNMB, which exhibits potent tumor-killing activity in multiple cancer types. This breakthrough opens new avenues for expanding the applicability of CAR T-cell therapy to solid tumors.
Technical / Clinical Details
The developed AI framework analyzes vast amounts of gene expression, proteomics, and clinical data to predict surface antigens highly expressed on cancer cells but minimally on normal tissues. This process incorporates expert biological knowledge to refine AI’s data-driven predictions. As a proof-of-concept, the team used this AI to identify GPNMB, a glycoprotein known to be overexpressed in various solid tumors, including breast cancer, melanoma, and glioblastoma. Preclinical studies in mouse models with GPNMB-targeted CAR T-cells demonstrated highly potent anti-tumor effects and a favorable safety profile across different solid tumors. These CAR T-cells effectively inhibited tumor growth and showed potential to address tumor types previously challenging for existing CAR T-cell therapies. The integration of AI significantly shortens the target discovery process from years to months, accelerating the development pipeline.
Background & Context
CAR T-cell therapy has shown remarkable efficacy against hematological malignancies like acute lymphoblastic leukemia and non-Hodgkin lymphoma. However, its application to solid tumors has faced multiple barriers, including the lack of specific and safe target antigens, the immunosuppressive tumor microenvironment, and issues with CAR T-cell infiltration and persistence within tumors. Crucially, the discovery of appropriate target antigens is key to the success of solid tumor CAR T-cell therapy, but this search is traditionally time-consuming and labor-intensive. The new AI framework addresses this bottleneck, offering a method to efficiently identify untapped targets, thereby potentially accelerating the development of CAR T-cell therapies for solid tumors. This technology is expected to contribute to the advancement of personalized medicine and the creation of new therapeutic options for patients with previously untreatable conditions.
Strategic Significance & Outlook
The GPNMB-targeted CAR T-cell therapy is expected to advance into early-phase human clinical trials, where its safety profile and efficacy in solid tumor patients will be thoroughly evaluated. This AI framework is also applicable to discovering novel targets beyond GPNMB, enriching the development pipelines for CAR T-cell therapies across various solid tumors and non-cancerous diseases like autoimmune conditions. The integration of AI with cellular immunotherapies is poised to not only accelerate therapeutic development but also pave the way for more personalized, effective, and safer next-generation cell therapies. This approach holds the potential to redefine the future of cancer treatment.
Source: https://www.pennmedicine.org/news/ai-framework-aids-target-discovery-for-car-t-cell-therapy
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments